Age-related macular degeneration Trials in Rapid City, United States
Conditions / Age-related macular degeneration / Rapid City, United States
Age-related macular degeneration is a medical condition with active clinical research programs worldwide.
14 total trials for this combination
Showing top 10 of 14 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00891735 | A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR) | COMPLETED | PHASE3 |
| NCT03891875 | ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA | COMPLETED | PHASE2 |
| NCT02727881 | Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD | UNKNOWN | PHASE3 |
| NCT06190093 | A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD) | COMPLETED | PHASE3 |
| NCT01940887 | A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy | TERMINATED | PHASE3 |
| NCT05536297 | Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy | COMPLETED | — |
| NCT01256827 | Seven Year Update of Macular Degeneration Patients | COMPLETED | — |
| NCT03150589 | A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD) | COMPLETED | PHASE3 |
| NCT01940900 | A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy | TERMINATED | PHASE3 |
| NCT03834753 | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) | COMPLETED | PHASE3 |